GlassScriptPhysician profile
Glen Lojka
NPI 1912903907
$44,592.03
in general payments reported to CMS, 2019-2025
24 companies · $5,216 in 2025
The $5,216 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,430 · 2020: $1,820 · 2021: $9,021 · 2022: $7,686 · 2023: $6,452 · 2024: $8,967 · 2025: $5,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Entertainment: $2,293 · Consulting Fee: $2,025 · Travel and Lodging: $1,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,686.73 |
| Entertainment | $2,292.77 |
| Consulting Fee | $2,025.00 |
| Travel and Lodging | $1,630.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $6,780.40 | 2019-2025 | Myday Contact Lens, Cvi Contact Lens, Biofinity Contact Lens |
| Sun Pharmaceutical Industries INC. | $5,679.26 | 2019-2023 | Cequa |
| Abbvie INC. | $4,948.86 | 2022-2025 | |
| Alcon Vision LLC | $4,570.28 | 2019-2025 | Precision 1, Total30, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $3,566.44 | 2022-2025 | Infuse, Biotrue One Day, Miebo |
| Allergan, INC. | $3,425.71 | 2019-2022 | |
| Optos, INC. | $2,973.83 | 2022-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Eyevance Pharmaceuticals LLC | $2,480.67 | 2020-2021 | |
| Sight Sciences, INC. | $1,954.12 | 2019-2025 | Tearcare System |
| Glaukos Corporation | $1,913.78 | 2019-2025 | Radius Xr, Idosetr, Photrexa Cross-Linking Kit |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,424.16 | 2019-2021 | |
| Lombart Brothers, INC. | $1,029.17 | 2021-2024 | Opd-III |
| Carl Zeiss Meditec USA, INC. | $703.23 | 2022-2025 | Lumera 700, Cirrus Hd-Oct, Atlas 500 |
| Lkc Technologies, INC. | $589.12 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $495.21 | 2022-2024 | Acuvue |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $453.35 | 2019-2022 | |
| Harrow Eye, LLC | $451.52 | 2024-2025 | Vevye |
| Dompe US, INC. | $411.10 | 2023-2025 | Oxervate |
| Carl Zeiss Meditec, INC. | $203.24 | 2020-2023 | Cirrus Hd-Oct |
| Haag-Streit USA, INC. | $144.71 | 2024 | |
| The Walman Optical Company | $111.58 | 2025 | |
| Apellis Pharmaceuticals, INC. | $106.00 | 2025 | Syfovre |
| Integra Lifesciences Corporation | $93.83 | 2020 | |
| Staar Surgical Company | $82.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Lojka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.